ArticleAnnals of translational medicine2022

Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.

Ying Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.